SENATE-BILL 2665: S.2665 - Drug Shortage Prevention Act of 2025
AI-Powered Summary
SENATE-BILL 2665 aims to enhance public health by ensuring continuous access to essential medications through mandatory notifications from drug manufacturers to the Secretary of Health regarding any disruptions in drug supply. The legislation addresses critical themes of individual health rights, access to healthcare, and regulatory oversight of the pharmaceutical industry, potentially invoking the Commerce Clause due to its implications on interstate drug manufacturing and distribution. Key provisions include the requirement for timely notifications to prevent drug shortages, a clear definition of 'covered drugs' focusing on life-supporting and life-sustaining medications, and an emphasis on transparency within the supply chain to improve patient safety. Implementation will require manufacturers to establish protocols for reporting supply issues, although specific timelines for compliance are not detailed in the bill. The potential impacts include improved patient access to necessary treatments, enhanced public health outcomes, and a balancing act between regulatory oversight and the economic freedoms of manufacturers, which may raise constitutional concerns regarding government intervention in private business operations.
Demographic Impact Analysis
Summary
Overall Constitutional Implications
The bill has significant positive implications for individual rights, particularly in enhancing access to necessary medications for various demographic groups. By mandating notification of drug shortages, it aims to protect public health and welfare.
Key Individual Rights Affected
- Right to Health Care
- Equal Protection under the Law
Constitutional Provisions
- 14th Amendment - Equal Protection Clause
- Implied Right to Health Care
Potential Constitutional Challenges Or Support
While the bill is likely to receive support for its public health objectives, challenges may arise regarding the potential burdens it places on manufacturers, which could affect drug availability and pricing. Additionally, if not implemented equitably, it could lead to disparities in access among different demographic groups, raising equal protection concerns.
Summary
The Drug Shortage Prevention Act of 2025 aims to improve the reliability of critical drug supplies, which is essential for vulnerable populations, including infants, seniors, and individuals with chronic illnesses. By requiring manufacturers to notify the government of potential shortages, the bill seeks to protect individual health rights and ensure equitable access to medications, aligning with constitutional principles.
Constitutional Analysis
This bill appears to align with constitutional principles. The proposed legislation operates within the established framework of constitutional authority and does not appear to conflict with fundamental rights or the separation of powers.
Analysis generated using AI-powered review of constitutional principles and legal precedents.
Take Action
Text 50409
💡 How to use:
These links will start a conversation with ResistBot. When prompted, mention S. 2665 to reference this bill.
Contact Your Representatives
Write to YOUR elected officials about this bill
Rate This Bill
Sign in to save a private rating for this bill and track your civic engagement over time.
Sign In FreePolicy Topics
Timeline
August 1, 2025
Bill Introduced
Current
Referred to Committee
June 12, 2026
Last Updated
Ask the Constitutional AI About This Bill
Sign in free to chat with our constitutional analysis AI about this bill — get plain-English explanations, constitutional concerns, and demographic impact estimates personalized to you.
Sign In Free to Chat